Department of Dermatology, University Hospital Birmingham, Birmingham, B15 2TH, UK.
Presse Med. 2022 Mar;51(1):104123. doi: 10.1016/j.lpm.2022.104123. Epub 2022 Apr 28.
PROCLIPI is the PROgnostic Cutaneous Lymphoma International Prognostic Index Study with the main aim to produce a prognostic index in mycosis fungoides (MF) and Sezary syndrome (SS). The study prospectively collects clinical, haematological, pathological, imaging, treatment with responses, quality of life and survival data using careful predefined datasets. Patients are subject to a central review to confirm diagnosis. PROCLIPI opened in 2015 and recruitment has been strong with to date 1916 patients recruited from 52 Centres from 19 countries across 6 continents.
PROCLIPI 是一项国际预后性蕈样真菌病和 Sezary 综合征预后指数研究，主要目的是建立蕈样真菌病（MF）和 Sezary 综合征（SS）的预后指数。该研究前瞻性地收集临床、血液学、病理学、影像学、治疗反应、生活质量和生存数据，并使用精心预设的数据集。患者需要进行中央审查以确认诊断。PROCLIPI 于 2015 年启动，招募工作非常顺利，截至目前已从六大洲 19 个国家的 52 个中心招募了 1916 名患者。
